45. 好酸球性多発血管炎性肉芽腫症 ［臨床試験数：27，薬物数：41（DrugBank：18），標的遺伝子数：18，標的パスウェイ数：98］
Searched query = "Eosinophilic granulomatosis with Polyangiitis", "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "Churg-Strauss syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||EUCTR2019-001832-77-DE||15/01/2020||21/08/2019||Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.||A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in patients receiving Standard of Care Therapy||Eosinophilic Granulomatosis with Polyangiitis (EGPA) |
MedDRA version: 20.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|Product Name: benralizumab|
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: Benralizumab
Trade Name: Nucala 100 mg powder for solution for injection
Product Name: mepolizumab
Product Code: L04AC06
INN or Proposed INN: Mepolizumab
Other descriptive name: Nucala
|AstraZeneca AB||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|140||Phase 3||United States;France;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy|